Search

Displaying results 5061 - 5070 of 10000 in total
  1. Drug

    Pegpleranib

    go.drugbank.com/drugs/DB06325
    Investigational

  2. Drug

    Transcrocetinate

    go.drugbank.com/drugs/DB05974
    Investigational

    Vitamin A-analog that increases diffusivity of oxygen in aqueous solutions, including plasma.

  3. Drug

    MBO7133

    go.drugbank.com/drugs/DB04999
    Experimental

    MB07133 is a HepDirect prodrug of an activated form of cytarabine (araC), an anti-cancer drug that is used to treat leukemia but is ineffective against primary liver cancer. … However, araC is only slowly converted to araCTP in the liver or in primary liver tumors due to low levels of an enzyme in the liver that is required for the conversion of araC to araCMP, the first step

  4. Drug

    GlycoPEG-GCSF

    go.drugbank.com/drugs/DB06022
    Experimental

    GlycoPEG-GCSF is a long-acting GlycoPEGylated granulocyte colony stimulating factor for the treatment of chemotherapy-induced neutropenia.

  5. Drug

    Droloxifene

    go.drugbank.com/drugs/DB15641
    Experimental

    Droloxifene, a derivative of the triphenylethylene drug tamoxifen, is a novel selective estrogen receptor modulator (SERM).

  6. Drug

    AR-9281

    go.drugbank.com/drugs/DB06345
    Investigational

    AR-9281 inhibits soluble epoxide hydrolase.

  7. Drug

    Racepinephrine

    go.drugbank.com/drugs/DB11124
    Approved

    It is an active ingredient in oral inhalation over-the-counter products as racepinephrine hydrochloride. … Racepinephrine is a racemic mixture consisting of d-[DB00668] and l-[DB00668] enantiomers. Epinephrine is a non-selective α- and β-adrenergic receptor agonist.

  8. Drug

    AZD-8330

    go.drugbank.com/drugs/DB06061
    Investigational

    AZD-8330 is a potent, selective, orally active MEK inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation and survival.

  9. Drug

    FX06

    go.drugbank.com/drugs/DB05685
    Investigational

    It is being developed by Fibrex Medical Inc. … FX06 is a naturally occurring peptide derived from the neo-N-terminus of fibrin (Bbeta(15-42)). It prevents leukocyte migration through the gap junctions of endothelial cells.

  10. Drug

    Varlitinib

    go.drugbank.com/drugs/DB05944
    Investigational

    Over-expression of ErbB-2 and EGFR receptors in tumors is predictive of poor prognosis in cancer patients. … Varlitinib is an oral, selective, reversible, small molecule tyrosine kinase inhibitor of both ErbB-2 (Her-2/neu) and EGFR.